Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 14/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18248281 | 0.75 | TERT (1.00) | TERTKMT2APOLB | |
| SCHEMBL18248286 | 0.73 | TERT (0.77) | TERTPOLB | |
| SCHEMBL12857443 | 0.69 | PTGS1 (1.00) | TERTPTGS1PTGS2MEN1KMT2A | |
| SCHEMBL18248369 | 0.69 | TERT (1.00) | TERT | |
| SCHEMBL18248445 | 0.67 | TERT (1.00) | TERTMEN1KMT2A | |
| SCHEMBL19710903 | 0.65 | ALDH1A1 (0.50) | PTGS1PTGS2MEN1KMT2AL3MBTL1 | |
| SCHEMBL31347868 | 0.64 | MEN1 (0.61) | MEN1KMT2AL3MBTL1POLB | |
| SCHEMBL11718417 | 0.64 | MEN1 (0.61) | MEN1KMT2AL3MBTL1POLB | |
| SCHEMBL19475408 | 0.64 | ITGB1 (0.45) | TERTPTGS1PTGS2MEN1KMT2A | |
| SCHEMBL18248229 | 0.63 | TERT (0.72) | TERTRIPK1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-05-13 | — | — | US | disclosed |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, MCL1 | TERT 3866/4885PTGS1 633/4885PTGS2 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.